ADA Forsyth, OrisDX team up on saliva testing for oral cancer detection
ADA Forsyth Institute and OrisDX are building a research partnership to generate clinical evidence for saliva-based molecular testing in dentistry. The effort could help dentists identify suspicious oral lesions earlier and guide how precision diagnostics fit into routine care.
Why it matters: - Oral cancer outcomes improve when suspicious lesions are found earlier. - The partnership aims to give dentists better evidence on whether saliva-based testing can help detect disease without immediately moving to biopsy. - The work could shape how precision medicine enters everyday dental practice, especially in underserved regions.
What happened: - OrisDX and the ADA Forsyth Institute announced an emerging strategic partnership on Oct. 13, 2026. - The collaboration links OrisDX’s saliva-based molecular diagnostics with ADA Forsyth’s Center for Clinical and Translational Research. - The two groups will also work with global collaborators to study emerging diagnostic tools for dental care.
The details: - The partnership will generate longitudinal clinical evidence on saliva-based testing and other emerging technologies. - ADA Forsyth will help develop evidence-based education and training for dental professionals. - The training will cover advanced genomic testing, biomedical imaging, innovative therapeutic modalities and next-generation diagnostic tools. - OrisDX’s platform is designed to help dentists and hygienists assess suspicious oral lesions using molecular insights. - The company’s technology grew out of research at the University of Chicago. - OrisDX uses a proprietary 7-gene panel. - The testing approach is non-invasive and saliva-based. - OrisDX says the goal is to identify malignancies in visible but indeterminate oral lesions. - The stated aims include reducing unnecessary biopsies and improving early-stage survival rates. - The collaboration also includes workflow integration work so the technology can fit evolving guidelines and regulatory approvals. - OrisDX’s website is More information. - ADA Forsyth’s website is More information. - OrisDX is also on LinkedIn at OrisDX on LinkedIn.
Between the lines: - Current American Dental Association guidelines say there is not enough peer-reviewed evidence to recommend saliva testing for broad clinical use. - That makes the partnership as much a validation effort as a product-development effort. - The focus on longitudinal studies and biodiverse cohorts signals an attempt to show how the technology performs across different patient groups and disease settings. - AFI’s participation gives the project research credibility, while OrisDX brings commercialization experience.
What's next: - The partners plan clinical studies to expand and update the evidence base. - They will build curriculum for dental hygienists and practitioners. - They will analyze emerging real-world data to assess performance across clinical settings. - The companies expect the work to inform when and how dental professionals should use these tools within established standards of care. - OrisDX says the long-term goal is evidence-based oral cancer detection in underserved regions.
The bottom line: - The partnership is trying to turn saliva testing from an emerging idea into a validated dental tool.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Illinois Business Review
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.